UAE Biosimilars Market Report 2026

BioNixus sizes the UAE biosimilars market at roughly USD 135 million in 2026, advancing toward about USD 275 million by 2030 at roughly 20% CAGR. The band triangulates Bonafide Research’s UAE outlook (>19.45% CAGR 2025–2030), Insights10’s monoclonal-antibody biosimilar trajectory ($35 million in 2022 to $175 million by 2030 at 22.3% CAGR), and supportive-care molecules (filgrastim, pegfilgrastim) listed in DOH’s August 2024 guideline. Growth is propelled by major biologic patent expiries, DOH treatment-naïve directives, SEHA inpatient mandates, and insurer cost control across immunology, oncology, and supportive care. Unlike Saudi Arabia, there is no single NUPCO tender: share accumulates through government policy in Abu Dhabi and insurer-by-insurer negotiation elsewhere. BioNixus treats the figure as a planning band rather than an audited total. Use the Saudi Arabia biosimilars report for the national-tender comparator, the GCC biosimilars report for Gulf-wide context, and the UAE healthcare market report for macro sizing.

Saudi Arabia substitutes primarily through NUPCO national hospital procurement awards that can move a molecule across hundreds of facilities in one cycle. The UAE has no equivalent single national tender. Instead, Abu Dhabi’s DOH August 2024 guideline directs treatment-naïve initiation on eight listed molecules, and SEHA mandates biosimilar use in inpatient settings—creating a policy-led channel in government facilities. Dubai and private insurers substitute through medical policy, step therapy, and hospital formularies emirate by emirate. Biologicals must be prescribed by brand name with no automatic pharmacy substitution, so even where policy favours biosimilars, switching is physician-led and patient-consented. The practical result is steadier, emirate-segmented uptake rather than a single step-change award. BioNixus maps these government and payer dynamics so developers and originators plan for a negotiated, confidence-dependent transition rather than one decisive procurement event.

Federal Decree-Law No. 38/2024 (effective January 2025) establishes the Emirates Drug Establishment (EDE) as the central federal authority for marketing authorisation, pharmacovigilance, and pricing oversight, with MOHAP functions transitioning to EDE. Article 7 permits biosimilar approval based on demonstrated equivalence to a reference product whose exclusivity has expired. DOH Abu Dhabi adds emirate-level requirements: biosimilars must be MOHAP-registered and DOH-approved, must meet EU or FDA quality standards, and—per the August 2024 guideline—should be initiated for treatment-naïve patients on eight listed molecules (adalimumab, etanercept, infliximab, trastuzumab, rituximab, bevacizumab, filgrastim, pegfilgrastim). Reimbursement runs through insurer medical policy (Thiqa, Daman, Dubai plans) and SEHA formularies rather than centralized tendering. Interchangeability is physician-led in consultation with the patient; automatic pharmacy substitution is not permitted for biologicals. BioNixus recommends mapping EDE/MOHAP registration, DOH or DHA facility access, and insurer substitution rules per emirate before launch, and revalidating policies frequently because DOH updates its biosimilar list and insurers revise medical policy on short cycles.

DOH’s August 2024 appendix lists eight active molecule categories: adalimumab, etanercept, infliximab (immunology anti-TNF), trastuzumab, rituximab, bevacizumab (oncology monoclonals), and filgrastim, pegfilgrastim (supportive care). These align with the highest-volume substitution waves as major biologic patents expire. Adalimumab leads on volume given rheumatoid arthritis and inflammatory bowel disease prevalence; trastuzumab and bevacizumab grow with rising oncology burden documented across UAE cancer registries. Activity concentrates in insured hospital and specialty channels rather than retail, and pace within each class depends on whether the patient is treatment-naïve (DOH-directed biosimilar start) or already established on an originator (insurer step therapy and clinician confidence govern switching). BioNixus tracks naïve-patient policy uptake separately from non-naïve switching so commercial teams prioritise molecules where substitution is accelerating rather than merely eligible.

Originators retain more defence room in the UAE than under Saudi NUPCO tendering, but face a tightening policy environment. DOH’s treatment-naïve mandate and SEHA inpatient rules erode the naïve-patient pool on eight core molecules, while non-naïve volume depends on insurer step therapy where device experience, patient-support programmes, indication breadth, and real-world evidence still influence retention. Because biologicals require brand-name prescribing and physician-led switching, confidence-building must be continuous—each insurer review and each non-naïve switch attempt is a fresh decision point. Stakeholder consensus in the UAE private sector targets first biosimilars at ≥30% below originator price, compressing margin for undifferentiated products. BioNixus runs prescriber switching and confidence studies and maps payer substitution incentives so originator teams concentrate spend on non-naïve cohorts, device-differentiated molecules, and payers where retention is achievable rather than over-investing where DOH policy has already shifted naïve starts.

BioNixus designs bilingual (Arabic–English) UAE biosimilar programmes for both developers and originators: prescriber confidence and switching studies across rheumatology, oncology, and gastroenterology; insurer and hospital-formulary interviews; DOH-listed-molecule and SEHA-policy mapping; EDE/MOHAP registration-pathway tracking; and KOL mapping tied to real formulary and switching influence. Deliverables align to biosimilar launch or originator-defence milestones and connect UAE findings to GCC benchmarks—notably the Saudi NUPCO tender model—only when a comparator truly informs governance. Typical outputs include molecule-wave models, naïve-versus-switched cohort maps, payer and switching maps, confidence and objection libraries, and committee-ready executive summaries. Begin from the healthcare market research hub or request a scoped briefing through the contact page.